YM BioSciences' experimental EGFR-targeted humanised monoclonal antibody drug nimotuzumab (YMB1000-015) will not progress to a pivotal trial in colorectal cancer at this time, but the Canadian company instead proposes to advance it into two other pivotal trials this year, including one in non-small cell lung cancer (NSCLC), which it believes could result in faster marketing approval.
YM's chief executive, David Allan, said the company was "most encouraged" by the results of a single-arm Phase II study testing nimotuzumab in patients with metastatic colorectal cancer plus the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?